{
    "text_blocks": {
        "data": {
            "block_count": 7,
            "table_index": 0
        },
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "votes": {
                    "0": "0",
                    "1": "0",
                    "2": "0"
                },
                "decision": "0"
            },
            "gpt-4o-2024-08-06": {
                "votes": null,
                "decision": null
            }
        },
        "timestamp": "2025-01-21_09-36-51"
    },
    "table_comments": {
        "data": "CONSOLIDATED BALANCE SHEETS\t(unaudited)\t(in millions, except per share amounts)\tMarch 31, 2023\tDecember 31, 2022\t",
        "timestamp": "2025-03-11_12-27-06"
    },
    "units": {
        "data": {
            "sum_units": 1000000,
            "sum_divider": 1.0
        },
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "votes": {
                    "0": "1000000",
                    "1": "1000000"
                },
                "decision": "1000000"
            },
            "gpt-4o-2024-08-06": {
                "votes": null,
                "decision": null
            }
        },
        "timestamp": "2025-03-11_12-27-09"
    },
    "post_table_text": {
        "data": "\tSee accompanying notes.\t3\tGILEAD SCIENCES, INC.\tCONDENSED CONSOLIDATED STATEMENTS",
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "trials": {
                    "0": "'\tSee accompanying notes.\t3\tGILEAD SCIENCES, INC.\tCONDENSED CONSOLIDATED STATEMENTS'"
                },
                "decision": "'\tSee accompanying notes.\t3\tGILEAD SCIENCES, INC.\tCONDENSED CONSOLIDATED STATEMENTS'"
            },
            "gpt-4o-2024-08-06": {
                "trials": {},
                "decision": null
            }
        },
        "timestamp": "2025-03-11_12-27-11"
    },
    "table_body": {
        "data": "Assets\tCurrent assets:\tCash and cash equivalents\t$\t4,936\t$\t5,412\tShort-term marketable debt securities\t936\t973\tAccounts receivable, net\t4,162\t4,777\tInventories\t1,576\t1,507\tPrepaid and other current assets\t1,846\t1,774\tTotal current assets\t13,456\t14,443\tProperty, plant and equipment, net\t5,479\t5,475\tLong-term marketable debt securities\t1,327\t1,245\tIntangible assets, net\t28,348\t28,894\tGoodwill\t8,314\t8,314\tOther long-term assets\t4,952\t4,800\tTotal assets\t$\t61,876\t$\t63,171\tLiabilities and Stockholders  Equity\tCurrent liabilities:\tAccounts payable\t$\t627\t$\t905\tAccrued rebates\t3,477\t3,479\tOther current liabilities\t4,140\t4,580\tCurrent portion of long-term debt and other obligations, net\t2,283\t2,273\tTotal current liabilities\t10,528\t11,237\tLong-term debt, net\t22,956\t22,957\tLong-term income taxes payable\t3,775\t3,916\tDeferred tax liability\t2,401\t2,673\tOther long-term obligations\t1,277\t1,179\tCommitments and contingencies (Note 10)\tStockholders  equity:\tPreferred stock, par value $\t0.001\tper share;\t5\tshares authorized;\tno\tne outstanding\t \t \tCommon stock, par value $\t0.001\tper share;\t5,600\tshares authorized;\t1,248\tand\t1,247\tshares issued and outstanding, respectively\t1\t1\tAdditional paid-in capital\t5,793\t5,550\tAccumulated other comprehensive income (loss)\t(\t20\t)\t2\tRetained earnings\t15,223\t15,687\tTotal Gilead stockholders  equity\t20,997\t21,240\tNoncontrolling interest\t(\t58\t)\t(\t31\t)\tTotal stockholders  equity\t20,939\t21,209\tTotal liabilities and stockholders  equity\t$\t61,876\t$\t63,171",
        "timestamp": "2025-03-11_12-27-11"
    },
    "table_json_created": {
        "data": true,
        "model": {
            "gpt-4o-mini-2024-07-18": {
                "trials": {
                    "0": "{\"Assets\": {\"Current assets\": {\"Cash and cash equivalents\": [4936, 5412], \"Short-term marketable debt securities\": [936, 973], \"Accounts receivable, net\": [4162, 4777], \"Inventories\": [1576, 1507], \"Prepaid and other current assets\": [1846, 1774], \"Total current assets\": [13456, 14443]}, \"Property, plant and equipment, net\": [5479, 5475], \"Long-term marketable debt securities\": [1327, 1245], \"Intangible assets, net\": [28348, 28894], \"Goodwill\": [8314, 8314], \"Other long-term assets\": [4952, 4800], \"Total assets\": [61876, 63171]}, \"Liabilities and Stockholders Equity\": {\"Current liabilities\": {\"Accounts payable\": [627, 905], \"Accrued rebates\": [3477, 3479], \"Other current liabilities\": [4140, 4580], \"Current portion of long-term debt and other obligations, net\": [2283, 2273], \"Total current liabilities\": [10528, 11237]}, \"Long-term debt, net\": [22956, 22957], \"Long-term income taxes payable\": [3775, 3916], \"Deferred tax liability\": [2401, 2673], \"Other long-term obligations\": [1277, 1179], \"Commitments and contingencies (Note 10)\": null, \"Stockholders equity\": {\"Preferred stock, par value $ 0.001 per share; 5 shares authorized; no none outstanding\": [0, 0], \"Common stock, par value $ 0.001 per share; 5,600 shares authorized; 1,248 and 1,247 shares issued and outstanding, respectively\": [1, 1], \"Additional paid-in capital\": [5793, 5550], \"Accumulated other comprehensive income (loss)\": [-20, 2], \"Retained earnings\": [15223, 15687], \"Total Gilead stockholders equity\": [20997, 21240], \"Noncontrolling interest\": [-58, -31], \"Total stockholders equity\": [20939, 21209]}, \"Total liabilities and stockholders equity\": [61876, 63171]}}"
                },
                "decision": "{\"Assets\": {\"Current assets\": {\"Cash and cash equivalents\": [4936, 5412], \"Short-term marketable debt securities\": [936, 973], \"Accounts receivable, net\": [4162, 4777], \"Inventories\": [1576, 1507], \"Prepaid and other current assets\": [1846, 1774], \"Total current assets\": [13456, 14443]}, \"Property, plant and equipment, net\": [5479, 5475], \"Long-term marketable debt securities\": [1327, 1245], \"Intangible assets, net\": [28348, 28894], \"Goodwill\": [8314, 8314], \"Other long-term assets\": [4952, 4800], \"Total assets\": [61876, 63171]}, \"Liabilities and Stockholders Equity\": {\"Current liabilities\": {\"Accounts payable\": [627, 905], \"Accrued rebates\": [3477, 3479], \"Other current liabilities\": [4140, 4580], \"Current portion of long-term debt and other obligations, net\": [2283, 2273], \"Total current liabilities\": [10528, 11237]}, \"Long-term debt, net\": [22956, 22957], \"Long-term income taxes payable\": [3775, 3916], \"Deferred tax liability\": [2401, 2673], \"Other long-term obligations\": [1277, 1179], \"Commitments and contingencies (Note 10)\": null, \"Stockholders equity\": {\"Preferred stock, par value $ 0.001 per share; 5 shares authorized; no none outstanding\": [0, 0], \"Common stock, par value $ 0.001 per share; 5,600 shares authorized; 1,248 and 1,247 shares issued and outstanding, respectively\": [1, 1], \"Additional paid-in capital\": [5793, 5550], \"Accumulated other comprehensive income (loss)\": [-20, 2], \"Retained earnings\": [15223, 15687], \"Total Gilead stockholders equity\": [20997, 21240], \"Noncontrolling interest\": [-58, -31], \"Total stockholders equity\": [20939, 21209]}, \"Total liabilities and stockholders equity\": [61876, 63171]}}"
            },
            "gpt-4o-2024-08-06": {
                "trials": {},
                "decision": null
            }
        },
        "timestamp": "2025-03-12_11-29-43"
    },
    "problems": {
        "data": [],
        "timestamp": "2025-03-12_11-29-43"
    }
}